Literature DB >> 16433799

Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity.

P Staubach1, A Eckhardt-Henn, M Dechene, A Vonend, M Metz, M Magerl, P Breuer, M Maurer.   

Abstract

BACKGROUND: Chronic urticaria (CU), one of the most common skin disorders, is characterized by spontaneous recurrent bouts of weals and pruritus and associated with severely impaired quality of life (QoL).
OBJECTIVES: To determine what aspects of life quality are affected and to characterize the factors that impact on QoL in CU patients. SUBJECTS AND METHODS: This interdisciplinary interview/questionnaire-based study included 100 patients admitted to a University Hospital Dermatology Department for the identification of underlying causes of CU; 96 healthy subjects matched for age and sex were used as controls. QoL was assessed using Skindex-29, a validated instrument to measure the effects of skin disease on overall QoL (composite score) and three defined QoL aspects (emotions, symptoms, functioning).
RESULTS: CU patients exhibited markedly reduced overall QoL compared with healthy control subjects. CU had distinct effects on the three QoL aspects assessed (functioning = emotions > symptoms). The age or sex of patients, the absence or presence of angio-oedemas, and the duration or cause of CU did not significantly influence QoL impairment. Interestingly, psychiatric comorbidity (depression, anxiety, somatoform disorders) was associated with a more pronounced reduction of QoL compared with CU patients without a psychiatric diagnosis and the severity of psychiatric disease was found to correlate with QoL impairment.
CONCLUSIONS: Our data confirm that overall QoL is markedly reduced in CU patients. Social functioning and emotions were found to be the areas of QoL most affected in CU patients. Psychiatric comorbidity significantly increased QoL impairment, whereas QoL in CU patients was not significantly affected by age or sex, the absence or presence of angio-oedema, or the course or cause of CU.

Entities:  

Mesh:

Year:  2006        PMID: 16433799     DOI: 10.1111/j.1365-2133.2005.06976.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  40 in total

1.  [Useful tools for documenting urticaria].

Authors:  P Staubach; A Groffik
Journal:  Hautarzt       Date:  2013-09       Impact factor: 0.751

Review 2.  [Chronic spontaneous urticaria: An autoimmune disease?].

Authors:  M Abajian; M Maurer; N Schoepke
Journal:  Hautarzt       Date:  2013-09       Impact factor: 0.751

Review 3.  [Selected psychosomatic aspects of dermatologic practice].

Authors:  A Stumpf
Journal:  Hautarzt       Date:  2012-10       Impact factor: 0.751

4.  Substance P is upregulated in the serum of patients with chronic spontaneous urticaria.

Authors:  Martin Metz; Clemens Krull; Tomasz Hawro; Rohit Saluja; Adriane Groffik; Christian Stanger; Petra Staubach; Marcus Maurer
Journal:  J Invest Dermatol       Date:  2014-05-20       Impact factor: 8.551

Review 5.  [Urticaria. "From bench to bedside"].

Authors:  M Magerl; M Maurer
Journal:  Hautarzt       Date:  2007-04       Impact factor: 0.751

6.  Subjective health and impaired quality of life due to allergies in a representative population survey.

Authors:  Thomas Dorner; Karl H Müller; Hannes Schmidl; Wolfgang Freidl; Willibald J Stronegger; Kitty Lawrence; Michael Kunze; Anita Rieder
Journal:  Wien Med Wochenschr       Date:  2007

Review 7.  Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.

Authors:  Claus Bachert; Marcus Maurer
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 8.  Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.

Authors:  Marcus Maurer; Kilian Eyerich; Stefanie Eyerich; Marta Ferrer; Jan Gutermuth; Karin Hartmann; Thilo Jakob; Alexander Kapp; Pavel Kolkhir; Désirée Larenas-Linnemann; Hae-Sim Park; Gunnar Pejler; Mario Sánchez-Borges; Knut Schäkel; Dagmar Simon; Hans-Uwe Simon; Karsten Weller; Torsten Zuberbier; Martin Metz
Journal:  Int Arch Allergy Immunol       Date:  2020-03-30       Impact factor: 2.749

9.  Desloratadine for the Relief of Nasal and Non-nasal Allergy Symptoms: An Observational Study.

Authors:  Werner Aberer
Journal:  Arch Drug Inf       Date:  2009-06

10.  Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study.

Authors:  Harold Kim; Charles Lynde
Journal:  Arch Drug Inf       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.